Human medicines European public assessment report (EPAR): Ebglyss, lebrikizumab, Date of authorisation: 16/11/2023, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 8 December 2025 - 11:55

Human medicines European public assessment report (EPAR): Ebglyss, lebrikizumab, Date of authorisation: 16/11/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Lyfnua, gefapixant, Date of authorisation: 15/09/2023, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 8 December 2025 - 10:40

Human medicines European public assessment report (EPAR): Lyfnua, gefapixant, Date of authorisation: 15/09/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 27, Status: Authorised

Submitted by Anonymous (not verified) on 8 December 2025 - 10:32

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 27, Status: Authorised

EMA/HMA annual data forum, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 9 December 2025, 09:00 (CET) to 9 December 2025, 17:30 (CET)

Submitted by Anonymous (not verified) on 8 December 2025 - 9:40

EMA/HMA annual data forum, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 9 December 2025, 09:00 (CET) to 9 December 2025, 17:30 (CET)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness